Dr. Sminu Bose, MD

Dr. Bose practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Bose's NPI, 1922498252, was assigned on January 26, 2015. Dr. Bose graduated from The Johns Hopkins University School of Medicine in 2017. Dr. Bose holds New York license 304284.

Dr. Bose's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Bose's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Bose to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bose practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Bose's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Bose is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Bose's licenses on file in 3 states: New York, Florida and New Jersey.

CMS data shows 216 Medicare services from Dr. Bose across 2 procedure codes in 2024, all of them office visits, for 76 Medicare patients. Medicare paid $21,061 for them. Every service was in an office.

CMS counts 76 Medicare patients who saw Dr. Bose in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bose's median patient age at 69, with 95% women.

In 2024, Dr. Bose wrote 296 Medicare Part D claims for 73 patients. 74% of them were for generic drugs. CMS names the drug for 161 of them, across 9 drugs with 11 or more claims each, at $254,013 in total drug cost. In 2023, CMS named 32 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Bose for performance year 2024, reported as part of a group. Dr. Bose accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bose as offering telehealth.

Dmand AI links 8 papers to Dr. Bose, published from 2020 to 2023. 2023 was the busiest year, with 2. The most frequent topics are Energy Metabolism, Glucose and Glycolysis. Dr. Bose has published most often in Adv Exp Med Biol. Dr. Bose's most frequent co-authors are Matthew Alfred Ingham, MD, Sosipatros A. Boikos, MD and Nam Quoc Bui, MD.

CMS Open Payments shows 4 general payments to Dr. Bose from 3 drug and device companies from 2020 to 2022. Education make up the largest share, 70% of the total. Incyte Corporation paid the most, $184.

Dr. Bose graduated from The Johns Hopkins University School of Medicine in 2017.

Dr. Bose is in network with 12 carriers, including Excellus BlueCross BlueShield, Elevance and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.